alexa Clinical Development Of A Novel Polyherbal Product For Treatment Of Atopic Dermatitis And Other Chronic Dermal Inflammatory Diseases
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th European Dermatology Congress
June 07-08, 2017 Milan, Italy

Manu Jaggi
Dabur Research Foundation, India
Keynote: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554-C1-055
Abstract
Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Current management strategies include oral medications, steroid creams and light therapy. We have developed a novel aqueous mixture (SIRB-001) consisting of three traditional Chinese medicine (TCM) based herbs; Rheum palmatum L. (Da Huang), Rehmannia glutinosa Libosch (Sheng di huang) and Lonicera Japonica (Jin yin hua) in the ratio 1:1:3. SIRB-001 based cream was developed and found to be highly safe in animal studies. SIRB-001 has previously demonstrated promising anti-psoriatic activity in pre-clinical models and clinical efficacy in psoriasis and scalp psoriasis. SIRB-001 exhibited anti-eczema properties in cell based models. Inhibition of cytokines and IgE was observed in keratinocytes (HaCaT)/immune cells and myeloma cell line-U-266, respectively. Inhibition of JAK-1/JAK-3 was induced by SIRB-001. Encouraging preclinical results paved the path for clinical investigations in atopic dermatitis. The efficacy, safety and tolerance of SIRB-001 cream were examined in 6-week clinical-dermatological application test in 25 subjects suffering from mild to moderate AD. With twice-daily application, SIRB-001 was very well tolerated and led to significant inhibition (p<0.001) in eczema area and severity index (EASI) with reduction of erythema, induration, excoriation and lichenification at 4 weeks and 6 weeks. Efficacious effect and tolerability of SIRB-001 cream was also evaluated in subjects with eczematous lesions in a mono-centric, open label study with twice daily application for 4 weeks. SIRB-001 cream demonstrated significant (p<0.001) decrease in eczema severity index (ESI), investigator's global assessment severity (IGAS) and was well-tolerated in human patients with a good safety profile. Inhibition of cytokines contributing to pathogenesis of AD; IL-8, IL-17A, TARC in serum samples was observed. It can be concluded that SIRB-001 is a highly effective new treatment with favorable safety profile for management of AD.
Biography

Manu Jaggi holds a Doctorate in Cancer Biology from National Institute of Immunology, Delhi and Post-graduate in Pharmaceutical Sciences. He is the Chief Scientific Officer of Dabur Research Foundation (DRF). He has extensive experience in the area of skin-care biology and screening of variety of cosmeceutical agents. He holds more than 100 patents and has published and presented more than 150 research papers in peer reviewed journals and scientific meetings. A comprehensive range of screening assays for studying the skin-health and anti-aging potential has been developed.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords